Ginkgo Bioworks was awarded a project agreement through BARDA’s BioMaP Consortium worth up to $22.2 million to develop cost-reducing approaches for domestic monoclonal antibody manufacturing against filoviruses (Ebola, Sudan). Ginkgo will lead partners including Advanced BioScience Laboratories, Isolere Bio, NeuImmune and ProteoNic BV to advance end-to-end innovations for producing an anti-filovirus mAb cocktail discovered at Emory University. BARDA framed the project as a national biosecurity priority to enable rapid, scalable mAb production.